Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease.

Purcaro C, Vanacore N, Moret F, Di Battista ME, Rubino A, Pierandrei S, Lucarelli M, Meco G, Fattapposta F, Pascale E.

Neurosci Lett. 2019 Jan 18;690:83-88. doi: 10.1016/j.neulet.2018.10.021. Epub 2018 Oct 11.

PMID:
30316985
2.

Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.

Kaplan N, Vituri A, Korczyn AD, Cohen OS, Inzelberg R, Yahalom G, Kozlova E, Milgrom R, Laitman Y, Friedman E, Rosset S, Hassin-Baer S.

J Mol Neurosci. 2014 Jun;53(2):183-8. doi: 10.1007/s12031-014-0276-9. Epub 2014 Mar 15.

PMID:
24633632
3.

Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.

Oliveri RL, Annesi G, Zappia M, Civitelli D, Montesanti R, Branca D, Nicoletti G, Spadafora P, Pasqua AA, Cittadella R, Andreoli V, Gambardella A, Aguglia U, Quattrone A.

Neurology. 1999 Oct 22;53(7):1425-30.

PMID:
10534246
4.

Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.

Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, Duhamel A, Delval A, Bardyn T, Devedjian JC, Rouaix N, Petyt G, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Azulay JP, Tison F, Destée A, Vidailhet M, Rascol O, Dujardin K, Defebvre L, Bordet R, Sablonnière B, Devos D; Parkgait-II Study Group.

Brain. 2015 May;138(Pt 5):1271-83. doi: 10.1093/brain/awv063. Epub 2015 Mar 23.

5.

Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.

Lee JY, Cho J, Lee EK, Park SS, Jeon BS.

Mov Disord. 2011 Jan;26(1):73-9. doi: 10.1002/mds.23400. Epub 2010 Oct 13.

PMID:
20945430
6.

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease.

Comi C, Ferrari M, Marino F, Magistrelli L, Cantello R, Riboldazzi G, Bianchi ML, Bono G, Cosentino M.

Int J Mol Sci. 2017 Jan 24;18(2). pii: E242. doi: 10.3390/ijms18020242.

7.

Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.

Yoo HS, Chung SJ, Chung SJ, Moon H, Oh JS, Kim JS, Hong JY, Ye BS, Sohn YH, Lee PH.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):423-431. doi: 10.1007/s00259-017-3844-8. Epub 2017 Oct 26.

PMID:
29075830
8.

The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease.

Dos Santos EUD, Sampaio TF, Tenório Dos Santos AD, Bezerra Leite FC, da Silva RC, Crovella S, Asano AGC, Asano NMJ, de Souza PRE.

J Pharm Pharmacol. 2019 Feb;71(2):206-212. doi: 10.1111/jphp.13031. Epub 2018 Oct 23.

PMID:
30353564
9.

MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients.

Martín-Flores N, Fernández-Santiago R, Antonelli F, Cerquera C, Moreno V, Martí MJ, Ezquerra M, Malagelada C.

Mol Neurobiol. 2019 Mar;56(3):2092-2100. doi: 10.1007/s12035-018-1219-1. Epub 2018 Jul 10.

PMID:
29992529
10.

L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.

Kaiser R, Hofer A, Grapengiesser A, Gasser T, Kupsch A, Roots I, Brockmöller J.

Neurology. 2003 Jun 10;60(11):1750-5.

PMID:
12796525
11.

Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.

Yahalom G, Kaplan N, Vituri A, Cohen OS, Inzelberg R, Kozlova E, Korczyn AD, Rosset S, Friedman E, Hassin-Baer S.

Parkinsonism Relat Disord. 2012 Nov;18(9):1039-41. doi: 10.1016/j.parkreldis.2012.05.014. Epub 2012 Jun 13.

PMID:
22703868
12.

Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.

Cheshire P, Bertram K, Ling H, O'Sullivan SS, Halliday G, McLean C, Bras J, Foltynie T, Storey E, Williams DR.

Neurodegener Dis. 2014;13(1):24-8. doi: 10.1159/000351097. Epub 2013 Sep 5.

13.
14.

Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.

Lin JJ, Yueh KC, Lin SZ, Harn HJ, Liu JT.

J Neurol Sci. 2007 Jan 31;252(2):130-4. Epub 2006 Dec 28.

PMID:
17196621
15.

Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.

Strong JA, Dalvi A, Revilla FJ, Sahay A, Samaha FJ, Welge JA, Gong J, Gartner M, Yue X, Yu L.

Mov Disord. 2006 May;21(5):654-9.

PMID:
16435402
16.

Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics.

Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gassó P, Catalan R, Mateos JJ, Lomeña F, Parellada E.

Schizophr Res. 2007 Feb;90(1-3):115-22. Epub 2006 Dec 5.

PMID:
17150335
17.

DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.

Rieck M, Schumacher-Schuh AF, Altmann V, Francisconi CL, Fagundes PT, Monte TL, Callegari-Jacques SM, Rieder CR, Hutz MH.

Pharmacogenomics. 2012 Nov;13(15):1701-10. doi: 10.2217/pgs.12.149.

PMID:
23171335
18.

Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3.

van de Giessen E, de Win MM, Tanck MW, van den Brink W, Baas F, Booij J.

J Nucl Med. 2009 Jan;50(1):45-52. doi: 10.2967/jnumed.108.053652. Epub 2008 Dec 17.

19.

Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.

Cheshire P, Ayton S, Bertram KL, Ling H, Li A, McLean C, Halliday GM, O'Sullivan SS, Revesz T, Finkelstein DI, Storey E, Williams DR.

Mov Disord. 2015 May;30(6):796-804. doi: 10.1002/mds.26144. Epub 2015 Feb 4.

PMID:
25649148
20.

Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.

Andersen AD, Blaabjerg M, Binzer M, Kamal A, Thagesen H, Kjaer TW, Stenager E, Gramsbergen JBP.

J Neurochem. 2017 May;141(4):614-625. doi: 10.1111/jnc.13997. Epub 2017 Mar 30.

Supplemental Content

Support Center